Expert Opinion on Optimizing Suboptimal Basal Insulin Titration in India: Addressing Challenges and Leveraging Digital Solutions.

IF 3.8 3区医学 Q2 Medicine

Diabetes Therapy Pub Date : 2025-05-20 DOI:10.1007/s13300-025-01747-2

Sanjay Kalra, Pramila Kalra, Kalyan Kumar Gangopadhyay, Sandeep Julka, Om J Lakhani, Manoj Chawla, Santhosh Ramakrishnan, Jasjeet Singh Wasir

{"title":"Expert Opinion on Optimizing Suboptimal Basal Insulin Titration in India: Addressing Challenges and Leveraging Digital Solutions.","authors":"Sanjay Kalra, Pramila Kalra, Kalyan Kumar Gangopadhyay, Sandeep Julka, Om J Lakhani, Manoj Chawla, Santhosh Ramakrishnan, Jasjeet Singh Wasir","doi":"10.1007/s13300-025-01747-2","DOIUrl":null,"url":null,"abstract":"<p><p>Basal insulin titration is crucial for achieving optimal glycemic control in patients with type 2 diabetes mellitus (T2DM), yet many patients and healthcare providers encounter persistent challenges in adjusting insulin doses to meet individualized targets. In October 2024, an expert panel of digital health specialists comprising endocrinologists, and diabetologists convened to discuss the limitations associated with suboptimal basal insulin titration and explore the potential of digital health solutions to address these issues. The discussion focused on how digital health tools like app-based services could facilitate more effective self-management, enhance patient engagement, and enable real-time communication in T2DM management. The panel's deliberations underscored the promise of digital health technologies as one of the means to overcome current complexities in basal insulin titration. By leveraging real-time data monitoring, remote consultations, and tailored treatment approaches, these tools offer a scalable progress to improving glycemic outcomes and overall diabetes management.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-025-01747-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Basal insulin titration is crucial for achieving optimal glycemic control in patients with type 2 diabetes mellitus (T2DM), yet many patients and healthcare providers encounter persistent challenges in adjusting insulin doses to meet individualized targets. In October 2024, an expert panel of digital health specialists comprising endocrinologists, and diabetologists convened to discuss the limitations associated with suboptimal basal insulin titration and explore the potential of digital health solutions to address these issues. The discussion focused on how digital health tools like app-based services could facilitate more effective self-management, enhance patient engagement, and enable real-time communication in T2DM management. The panel's deliberations underscored the promise of digital health technologies as one of the means to overcome current complexities in basal insulin titration. By leveraging real-time data monitoring, remote consultations, and tailored treatment approaches, these tools offer a scalable progress to improving glycemic outcomes and overall diabetes management.

查看原文本刊更多论文

关于优化印度次优基础胰岛素滴定的专家意见：应对挑战并利用数字解决方案。

基础胰岛素滴定对于2型糖尿病（T2DM）患者实现最佳血糖控制至关重要，但许多患者和医疗保健提供者在调整胰岛素剂量以满足个体化目标方面面临持续挑战。2024年10月，一个由内分泌学家和糖尿病学家组成的数字健康专家小组召开会议，讨论与次优基础胰岛素滴定相关的局限性，并探讨数字健康解决方案解决这些问题的潜力。讨论的重点是基于应用程序的服务等数字健康工具如何促进更有效的自我管理，提高患者参与度，并在T2DM管理中实现实时沟通。该小组的审议强调了数字健康技术作为克服目前基础胰岛素滴定复杂性的手段之一的前景。通过利用实时数据监测、远程咨询和量身定制的治疗方法，这些工具为改善血糖结果和整体糖尿病管理提供了可扩展的进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes Therapy Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

6.90

自引率

7.90%

发文量

130

审稿时长

6 weeks

期刊介绍： Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.